

Discover  
your **new** sight,



IT'S **KANARB**

NEW



**Khan(The ruler) of ARB**  
NCE antihypertensive drug

**Kanarb®**  
Fimasartan



Kanarb recorded 10 Million USD sales in the year of its launch in March, 2011. Ever since then it has been maintaining the No.1 position in the ARB market in Korea. Kanarb was also acknowledged to have clinical values in Mexico and Russia.


**Kanarb®**  
Fimasartan  
**Kanarb® Plus\***  
Fimasartan + HCTZ

**Dukarb®**  
Fimasartan + Amlodipine  
**Tuvero®**  
Fimasartan + Rosuvastatin

**Dukard®**  
Fimasartan/Amlodipine/Rosuvastatin  
**Akarb®**  
Fimasartan + Lisinopril



### ◀ ARB from Korea, Boryung Pharmaceutical

The journey to be a leading pharmaceutical company in Korea




### ◀ Global Manufacturing Execution System in Yesan Smart Factory

The entire process including manufacturing, packaging, and shipping is fully automated at once.



### Out-licensing Deals in 42 countries

Globally Kanarb has been licensed out in 42 countries



- CHINA Licensing opportunities: Open
- CIS Licensing opportunities: Open
- Mongolia: Mono: Open/LLC
- EU Licensing opportunities: Open
- JAPAN Licensing opportunities: Open
- KOREA Mono & All Combs: Boryong / HCTZ Combs: Dongwha
- RUSSIA Mono: With Phazim / All Combs: Open
- 10 AMERICAN COUNTRIES Mono & HCTZ Combs: With Koro / Other Combs: Open
- AFRICA Licensing opportunities: Open
- ASIAN COUNTRIES Mono & All Combs: With Zeelgi (SG/PH/TH) / Other Combs: Open
- AUSTRALIA Licensing opportunities: Open
- MEXICO & LATIN 24 COUNTRIES Mono & All Combs: With Sherdel
- NORTH AMERICA Licensing opportunities: Open
- BRAZIL Licensing opportunities: Open

### Status of Kanarb's Valuable Studies

**100**  
Over 100 studies


**45,000**  
More than 45,000 patients enrolled

**10**  
Over 10 ongoing clinical trials

### Expanding the spectrum of Kanarb

There are various single-pill combinations available and ongoing clinical studies in progress to cover not only hypertension, but also other diseases such as metabolic syndrome, CKD, stroke, etc.

Upcoming Clinical Studies Of Kanarb



### Boryong, the Moving Frontier with Kanarb

Strives to expand into a new market

Kanarb has displayed its market and clinical values which successfully led to:

**2014**  
Avalide (fimasartan) launched in Mexico

**2015**  
Borel® (nor-pseudoephedrine) launched in Philippines

**2016**  
Disvalide (fimasartan/ hydrochlorothiazide) launched in Mexico

**2018**  
Kanarb launched in Asia: Singapore and Malaysia

**2019**  
Kanarb launched in Philippines and Thailand

**2019**  
Another One (fimasartan/ amlodipine) launched in Philippines


**2020**  
Another One (fimasartan/ renin-inhibitor) launched in Philippines

## ◀ Kanarb, the one of the latest ARBs


Kanarb provides the better treatment option by its valuable clinical results.

## clinical

### • Rapid results with Kanarb



### • Improved BP control with less variability with Kanarb



### • Good safety profile

**2.35%** Adverse event (n=14,151)  
 0% Serious adverse drug reaction in the PMS study (n=2,893)

For more information, visit [www.kanarb.com](http://www.kanarb.com)

### • Effective and safe in a wide spectrum of patient populations




**Mexican patients**  
 For more information, visit [www.kanarb.com](http://www.kanarb.com)

**Russian patients**  
 For more information, visit [www.kanarb.com](http://www.kanarb.com)

## nonclinical

### • Kanarb's favorable PK/PD characteristics



## clinical

### • Improved efficacy of Kanarb



**Kanarb<sup>®</sup>**  
Fimasartan

**B  
R**  
**BORYUNG**  
Pharmaceutical

BORYUNG PHARMACEUTICAL CO., LTD  
Boryung Bldg, Changgyeonggung-ro 136, Jongno-gu, Seoul, Korea, 03127